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Abstract
Background: Two-hybrid screening for proteins that interact with the core domain of human
topoisomerase I identified two novel proteins, BTBD1 and BTBD2, which share 80% amino acid
identities.
Results: The interactions were confirmed by co-precipitation assays demonstrating the physical
interaction of BTBD1 and BTBD2 with 100 kDa topoisomerase I from HeLa cells. Deletion
mapping using two-hybrid and GST-pulldown assays demonstrated that less than the C-terminal
half of BTBD1 is sufficient for binding topoisomerase I. The topoisomerase I sequences sufficient
to bind BTBD2 were mapped to residues 215 to 329. BTBD2 with an epitope tag localized to
cytoplasmic bodies. Using truncated versions that direct BTBD2 and TOP1 to the same cellular
compartment, either the nucleus or the cytoplasm, co-localization was demonstrated in co-
transfected Hela cells. The supercoil relaxation and DNA cleavage activities of topoisomerase I in
vitro were affected little or none by co-incubation with BTBD2. Northern analysis revealed only a
single sized mRNA for each BTBD1 and BTBD2 in all human tissues tested. Characterization of
BTBD2 mRNA revealed a 255 nucleotide 90% GC-rich region predicted to encode the N-terminus.
BTBD1 and BTBD2 are widely if not ubiquitously expressed in human tissues, and have two paralogs
as well as putative orthologs in C. elegans and D. melanogaster.
Conclusions: BTBD1 and BTBD2 belong to a small family of uncharacterized proteins that appear
to be specific to animals. Epitope-tagged BTBD2 localized to cytoplasmic bodies. The
characterization of BTBD1 and BTBD2 and their interaction with TOP1 is underway.
Background
DNA topoisomerase I (TOP1) is a ubiquitously expressed
protein that relaxes DNA supercoils generated during
many transactions of DNA including replication, tran-
scription, repair, and chromatin condensation and re-
modeling. TOP1 has been shown to interact with many
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proteins including components of the holo TFIIIC com-
plex [1], TFIID [2], p53 [3], SV-40 large T antigen [4], nu-
cleolin [5], the RING finger protein topors [6], the RNA
splicing factors PSF/p54nrb[7] and SF2/ASF [8], the cell cy-
cle regulatory protein ARF [9], RNA pol II complex
[10,11], and HTLV type 1 tax oncoprotein [12]. TOP1 also
interacts with a variety of unidentified proteins involved
in its phosphorylation, ubiquitination and sumoylation
[13–17].
We used the core domain of TOP1 lacking the N-terminal
highly charged region, the coiled-coil linker domain and
the C-terminal active site domain as bait in two hybrid
screens for TOP1 interacting proteins. We obtained multi-
ple independent cDNA clones coding for BTBD1 and
BTBD2, two uncharacterized, BTB domain-containing,
kelch-like proteins. The interactions of HeLa cell TOP1
with the BTBD proteins was confirmed using GST-pull-
down and was further suggested by their intracellular co-
localization.
Results
Identification of TOP1-interacting proteins using two-hy-
brid assays
The core domain of human TOP1 from residue 198 to 651
was used as the bait in two-hybrid screens [18–20]. This
region of TOP1 lacks the N-terminal ~25% of the protein
that is highly charged and the C-terminal domain con-
taining the active site and the coiled-coil linker. The result-
ing polypeptide comprises 60% of the TOP1 sequence. A
screen of a HeLa cell library yielded 56 colonies that tested
positive in the two hybrid assays (growth on plates lacking
histidine or uracil, lack of growth on plates containing 5-
fluoroorotic acid; and induction of lacZ resulting in blue
color when assayed with X-gal). Nucleotide sequence
analysis of 34 of these clones revealed two cDNA contigs
of 15 and 19 that predict proteins whose sequences are
80% identical. The proteins were named BTBD1 and
BTBD2 according to a recent analysis of their genomic se-
quences [21]. The clones of each contig differed in the
amount of 5' sequence present: 11/15 and 15/19 of
BTBD1 and BTBD2, respectively, had different 5' ends. In
the two-hybrid growth assays and β -galactosidase assays,
each of the clones tested as positive as the control for
strongly interacting proteins (the interaction of c-Fos with
c-Jun, ProQuest, Life Technologies). Another two-hybrid
screen using a different two-hybrid system (Matchmaker,
Clontech) also yielded 2 clones identical to the contig of
15 clones (BTBD1).
Characterization of BTBD1 and BTBD2 mRNA
The longest BTBD1 cDNA clone obtained from two-hy-
brid screening (3196 bp) contains an ORF that encodes a
482 aa protein starting with an ATG that is preceded by an
in-frame stop codon. Sequences in GenBank confirmed
our sequence. One was obtained by the oligo-capping
method (FLJ20724), and another assembled from partial
cDNA and RACE fragments [21].
The longest BTBD2 cDNA obtained from two-hybrid
screening (2413 bp) contained an ORF starting at the 5'
end. To obtain the missing 5' cDNA, a nested PCR strategy
was used to amplify the sequence from four independent
cDNA libraries, but no extended sequences were obtained.
5'-RACE (Life Technologies) also failed to produce longer
clones. This difficulty to obtain longer cDNA clones was
seen by others [21]. The GC richness at the 5' end (85 nu-
cleotides are 79% GC) may form secondary structures that
block reverse transcriptase. Analysis of the BTBD2 gene
immediately upstream of the 5' end of our cDNA predicts
an ORF that begins with an ATG and encodes 85 amino
acids in-frame with the ORF of our longest BTBD2 clone;
however, the 255 nucleotides encoding these in-frame
amino acids sequence are 89% GC rich. To determine if
this sequence might be part of the BTBD2 mRNA, RT-PCR
followed by nested PCR was used. Two antisense primers
complementary to exon 2 were used to prime reverse tran-
scription. Sense primers for PCR amplification were locat-
ed within predicted exon 1 (Fig. 1A). Amplified products
of 460 and 306 bp that are predicted from the mRNA tem-
plate resulted (Fig. 1B). If genomic DNA had been the
template, products greater than 18 kb would have been
obtained. Furthermore, sequencing of the 460 bp-ampli-
fication product confirmed it to be the predicted mRNA
(Fig. 1A). The cDNA starting at the predicted start codon
was deposited in GenBank (AF355797).
Northern blotting and in silico expression analysis
Northern blotting was used to determine the tissue distri-
bution and sizes of the mRNA encoding BTBD1 and
BTBD2 (Fig. 2). Poly (A)+RNA from human tissues (2 µg/
lane) was probed with BTBD1, BTBD2 or TOP1 cDNA.
Each mRNA was detected in all the tissues tested. BTBD1
mRNA was highly expressed in testes, heart and skeletal
muscle. BTBD2 was more highly expressed in skeletal
muscle. Only a single message size was detected for each
BTBD1 (3.2 kb) and BTBD2 (2.8 kb).
BTBD1 and BTBD2 cDNA were found in libraries from the
following tissues: amniotic, aorta, bone, brain, bone mar-
row, colon, ear, embryo, foreskin, gall bladder, germ,
heart, kidney, lung, muscle, ovary, pancreas, parathyroid,
placenta, skin, spleen, stomach, testis, thymus, tonsil and
uterus (LocusID 53339 and 55643, respectively [22]).
BTBD1 and BTBD2 was also expressed in a large number
of tumor types and normal tissues present in SAGE (serial
analysis of gene expression) libraries (SAGEmap, [23]).BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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Mapping of the regions of TOP1 and the BTBDs that inter-
act
BTBD1 and BTBD2 were mapped by deletion analysis to
identify amino acid sequences required for interaction
with TOP1. In two-hybrid assays, N-terminal deletions of
~36 % of BTBD1 (177 aa) or 43% BTBD2 (228 aa) did not
eliminate binding to TOP1 (Fig. 3A+B). In contrast, C-ter-
minal deletions of 112 and 33 aa of BTBD1 and BTBD2,
respectively, eliminated binding to TOP1 in the two-hy-
brid assays. Thus sequences very close to the C-terminus
are required for the interaction with TOP1 by this analysis.
Two-hybrid analysis was also used to map regions of the
TOP1 core domain that interact with BTBD2. The region
upstream of aa 215 and downstream of aa 329 were not
required for binding BTBD2 (Fig. 3C). The fragment of
TOP1 from amino acid 215 to 331 was capable of binding
to BTBD2. This region includes 18 aa of core subdomain
I, all of core subdomain II and 10 amino acids of the sec-
ond section of core subdomain I.
GST-pulldown assays confirm two-hybrid deletion map-
ping
Truncated fragments of BTBD1 and BTBD2 were tested in
GST-pull down assays for their ability to bind TOP1 in nu-
clear extracts of HeLa cells. The GST-pulldown assay con-
firmed the positive interactions seen in the two-hybrid
deletion mapping (Fig. 4). In addition, we found that two
N-terminal truncated BTBD1 and BTBD2 were able to co-
precipitate TOP1 from nuclear extracts (BTBD1, 213–482
& 303–482; BTBD2, 249–525 & 289–525) although they
were negative in the two-hybrid assay. Since truncated
fragments may be unstable in yeast and may not accumu-
late to levels sufficient to produce a positive result, we
used roughly equal amounts of each truncated protein to
test for binding to TOP1 in nuclear extracts. Taken togeth-
er, the results of the two-hybrid and GST-pulldown assays
narrow the interacting region of BTBD1 and BTBD2 to
roughly the C-terminal half of each protein with critical
residues within the last 50 residues.
Effect of GST-BTBD2 on TOP1 activity
To test the effect of BTBD2 on the supercoil relaxation ac-
tivity of TOP1, HeLa cell nuclear extracts containing TOP1
were incubated with GST or GST-BTBD2 (aa 86–525).
GST-BTBD2 slightly inhibited the supercoil relaxation ac-
tivity of TOP1, increasing the time required to completely
relax the supercoiled DNA by about two-fold as compared
with GST alone (Fig. 5A). The DNA cleavage assay was
also used to determine if BTBD2 affected TOP1 activity.
This assay measures the ability of TOP1 to cleave end-la-
beled DNA substrates in the presence of the anticancer
drug camptothecin, which blocks the ligation step of the
cleavage /religation reaction of TOP1. A 36 bp DNA con-
taining a single strong TOP1 cleavage site [24] or a 161 bp
restriction fragment [25] was used as the substrate. GST-
BTBD2 addition produced a slight inhibition of TOP1
cleavage activity relative to GST alone (Fig. 5B) on the
smaller substrate and had no detectable effect on cleavage
activity or cleavage site selection by TOP1 on the larger
substrate (5C).
Cellular localization of BTBD2 and co-localization with 
TOP1
To determine the localization of BTBD2 in cells, we tran-
siently transfected HeLa cells with expression plasmids
encoding either myc-tagged full length BTBD2 (m-
BTBD2F) or a truncated BTBD2 having the N-terminal
half of the BTB domain removed (m-BTBD2T). The full
length BTBD2 localized entirely to cytoplasmic bodies
(Fig. 6B, m-BTBD2F). The truncated BTBD2 localized pre-
dominantly to nuclear bodies with a minor fraction local-
izing to cytoplasmic bodies (Fig. 6C, m-BTBD2T).
Figure 1
RT-PCR identifies a highly GC-rich sequence predicted to
encode the ammo terminal region of BTBD2. A. RT-PCR
strategy and the sequence of the amplified region are shown:
BTBD2 coding region (open arrow), 3'-UTR (narrow open
bar) and exons (wide open bar, 1 – 9), sense primers (UO
and UI), antisense primers (LI and LO), GC-rich region (solid
bar and sequence). B. Products of the RT-PCR are shown on
an ethidium bromide gel. Reverse transcription was per-
formed with antisense primers complementary to exon 2.
The schematic shows the relevant portion of the mRNA
template, the RT primers (LI and LO), the sense primers
(UO and UI), and the amplified products (460 and 306 bp)
that correspond to the bands on the agarose gel stained with
ethidium bromide (lanes 1 & 2, DNA size standards; lane
3, product of reverse transcription with LO, 1st round PCR
with UO and LO, and 2nd round PCR with UO and LI; lane
4, product of reverse transcription with LO, 1st round PCR
with UO and LO, and 2nd round PCR with UI and LO.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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The localization of full length BTBD2 to cytoplasmic bod-
ies was surprising because the cytoplasm is separated from
the nucleus where endogenous TOP1 resides and trans-
fected GFP-TOP1 localizes [26–30]. Because TOP1 and
BTBD2 are not predominantly found in the same com-
partments, they may interact transiently, or they may in-
teract only under specific conditions when they may be in
the same compartment. We therefore analyzed mitotic
cells, but did not observe co-localization of TOP1 and the
BTBDs (not shown). We then tested for co-localization in
transfected cells. Though the truncated m-BTBD2T local-
ized to distinct nuclear bodies, its co-localization with en-
dogenous TOP1 could not be determined against the
background of endogenous TOP1 diffuse nuclear stain-
ing. However, in cells co-transfected with GFP-TOP1 and
m-BTBD2T, the m-BTBD2T staining was nuclear diffuse as
well as in nuclear bodies, indicating that m-BTBD2T inter-
acts with GFP-TOP1, which localizes throughout the nu-
cleus (not shown).
To determine if TOP1 co-localizes with BTBD2 in the cy-
toplasm, GFP-TOP1 lacking an NLS [30] was co-transfect-
ed with full length BTBD2 (m-BTBD2F) or truncated
BTBD2 (m-BTBD2T). GFP-TOP1 lacking a NLS (GFP-pTI-
6) localizes diffusely within the cytoplasm (Fig. 6A and
[30]). In cells transfected with both GFP-pTI-6 and full
length m-BTBD2F, the diffuse cytoplasmic GFP-pTI-6 sig-
nificantly decreased, and GFP-pTI-6 co-localized with m-
BTBD2F to cytoplasmic bodies (Fig. 6D). In cells transfect-
ed with GFP-pTI-6 and truncated m-BTBD2T, truncated
m-BTBD2T was not in nuclear bodies as when transfected
alone, rather it co-localized with GFP-pTI-6 to cytoplas-
mic bodies (Fig. 6E). Thus, when co-transfected with GFP-
TOP1 lacking a NLS, both full length and the N-terminal
deleted BTBD2 co-localized with TOP1 to cytoplasmic
bodies.
Discussion
Two-hybrid screens have identified BTBD1 and BTBD2 as
proteins that interact with the core domain of TOP1.
BTBD1 and BTBD2 were isolated as 15 and 19 independ-
ent clones, respectively, and in two-hybrid assays they in-
teracted as strongly as the control for strongly interacting
proteins (c-Fos with c-Jun). BTBD1 and BTBD2 also
bound HeLa cell TOP1 (100 kDa) in nuclear extracts by
GST-pulldown assays. N-terminal truncation studies
showed the C-terminal 37% to 45% of the BTBD proteins
are sufficient for binding TOP1. C-terminal deletions of
either protein eliminated binding to TOP1 (C-terminal
truncation of 112 aa of BTBD1 or 33 aa of BTBD2 in the
two-hybrid assay; or a C-terminal truncation of 40 aa of
BTBD2 in GST-pulldown). Truncation of the BTB do-
mains demonstrated that they were not required for inter-
action with TOP1. The region of TOP1 sufficient for
Figure 2
BTBD1 and BTBD2 Northern blots of human tissues. Multi-
ple Tissue Northern (MNT™, Clontech) blots were probed
with  32P-dCTP-labeled cDNA (TOP1, BTBD1 or BTBD2).
Each lane contains 2 µg of polyA+RNA from each tissue. A.
1. spleen, 2. thymus, 3. prostate, 4. testes, 5. uterus, 6. small
intestine, 7. colon, 8. leukocytes. B. 1. heart, 2. brain, 3. pla-
centa, 4. lung, 5. liver, 6. skeletal muscle, 7. kidney, 8. pla-
centa. The membranes were re-probed for actin.
Figure 3
Deletion mapping of the interacting regions of TOP1 and
BTBD1 and BTBD2 using two-hybrid assays.A. Deletions of
BTBD1 and their interaction with cTOP 1 (residues 198–
651).  B. Deletions of BTBD2 and their interaction with
cTOP1. C. Deletions of cTOP1 and their interaction with
BTBD2. Interactions were tested using colony formation
assays on plates lacking histidine or uridine and the β -galac-
tosidase colony color assay. The TOP1 core domain regions
are shown from N- to C-terminus: subdomain I (yellow),
subdomain II (blue), subdomain I (yellow) and subdomain III
(red). The shortest clones obtained from two-hybrid screen-
ing were downstream of the BTB domains, beginng at residue
186 and 219 for BTBD1 and BTBD2, respectively. Results are
summarized for the two-hybrid (2-hyb) and the GST-pull
down assays (Gst-PD, see Fig. 4)BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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binding BTBD2 was narrowed to residues 215 – 329 in the
"cap" region (core subdomain II) [31]. Catalytic activities
of TOP1 were affected slightly or not at all by co-incuba-
tion with GST-BTBD2 suggesting that the interaction does
not regulate enzyme activity directly.
We cloned the full length BTBD1 cDNA from a HeLa cell
library. This sequence is 3196 bp, and the start codon is
preceded by a stop codon 6 nucleotides upstream (Gen-
Bank, FLJ20724). Our sequence is comparable to two oth-
ers in GenBank, one of which was obtained by the oligo-
capping method suggesting that it begins at the 5' cap
[21,32].
Our repeated attempts to clone the 5' end of the BTBD2 by
library screening and the RACE method were unsuccess-
ful. We tested sequences directly upstream of the longest
cDNA in the BTBD2 gene for their presence on the mRNA.
RT-PCR and sequencing of the RT-PCR product demon-
strated that this 255 nucleotide, 89% GC-rich sequence is
present on the BTBD2 mRNA and that it shares predicted
polypeptide sequence with BTBD homologues and or-
thologs.
The BTBD proteins contain an amino terminal BTB/POZ
domain as well as a C-terminal region that is related to
proteins that contain the kelch domain. Neither of these
regions yields unequivocal information for functional
classification. The BTB domain is a highly conserved 120
amino acid, hydrophobic-rich, protein-protein interac-
tion domain that mediates homodimerization and het-
erodimerization of a large number of proteins with
diverse functions [9]. The three dimensional structure of
one BTB domain [33] has been characterized through
structure-function studies [34]. Proteins containing BTB
domains are currently categorized into three groups [35]:
1) DNA-binding proteins often containing zinc fingers in
the C-terminal region, 2) actin binding proteins that con-
tain a kelch repeat of ~50 residues that terminate in a pair
of glycine residues [36] and 3) proteins that have neither
an actin-binding domain nor a DNA-binding domain.
The BTBD proteins belong to the last category, although
they are distantly related to kelch proteins (~25% identi-
cal over ~250 aa), they lack the residues that are character-
istic of kelch repeats, a double glycine sequence and a
tyrosine separated from a tryptophan by precisely 6 resi-
dues [35,37].
BTBD1 and BTBD2 are closely related sharing 80% identi-
cal amino acid sequence. They are one of eleven genes in
19p13.3 →  p12 with close homology to genes in 15q24 →
q26 that have apparently resulted from duplications of a
common ancestral gene [38]. Both BTBD1 and BTBD2 are
widely if not ubiquitously expressed in human tissues.
The predicted promoter regions are highly GC-rich and
lack canonical TATA boxes, suggesting that they may be
housekeeping genes [39,40].
Close mammalian relatives of BTBD1 and BTBD2 include
the mouse orthologs that are 98% and 95% identical re-
spectively, as well as highly similar rat and bovine partial
sequences [21]. Sequence relatives in lower organisms in-
clude a C. elegans sequence with 58% identities with
BTBD2 (429 residues; 2% gaps, F38H4.7), and a D. mela-
nogaster sequence with 46% identities (437 residues, 3%
gaps, CG5319). The human genome encodes two proteins
with 46% (436 residues, 3% gaps, CAC22147) and 45%
(497 residues, 5% gaps, AF353674) identities compared
with BTBD2. These proteins comprise a small family
whose members have not been functionally characterized
and are evidently specific to animals because putative or-
thologs are not present in available fungi and plant se-
quence databases.
We have demonstrated an interaction between BTBD2
and TOP1 by two-hybrid, GST-pull down and intracellu-
Figure 4
TOP1 from HeLa cells interacts with GST-BTBD1 and GST-
BTBD2.A.TOP1 Western blot. HeLa cell nuclear extracts were
incubated with GST or GST-BTBD2 beads. After washing,
the beads were solubilized in SDS-PAGE sample buffer and
subjected to SDS-PAGE and Western blotting with TOP1
antiserum. B.Coomassie Blue stained gel showing the quantity
of GST and GST fusion proteins added to the binding reac-
tions (*). METHODS: GST-BTBD1 or GST-BTBD2 was
expressed and purified from E. coli extracts. ~5 µg of GST or
the GST-fusion proteins were mixed with HeLa cell nuclear
extracts and incubated for 2 hr at 4°C (0.25 M NaCl). The
bead pellets were then washed 3 times with ice cold PBS
before solubilization in SDS sample buffer. One tenth of the
nuclear extract used in the binding reaction was loaded in the
lanes labeled "HeLa extract". Arrow shows co-precipitated
TOP1.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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lar co-localization analyses. Studies are underway to func-
tionally characterize BTBD1 and BTBD2 and understand
their interaction with TOP1.
Conclusions
• Fifteen and nineteen independent cDNA clones of
BTBD1 and BTBD2, respectively, were isolated from two-
hybrid screens and found to interact as strongly as c-Fos
interacted with c-Jun in the two-hybrid assays.
• The interactions of TOP 1 with BTBD1 and BTBD2 were
confirmed by deletion mapping using two-hybrid and
GST-pulldown assays.
• Less than the C-terminal half of each BTBD protein lack-
ing the BTB domain is sufficient for binding to TOP1.
TOP1 from aa 215 to 329 interacted with BTBD2.
• GFP-BTBD2 localized to cytoplasmic bodies.
• BTBD2 had little effect on the supercoil relaxation or
DNA cleavage activity of TOP1 in vitro.
• Co-transfected BTBD2 and TOP1 co-localized.
• The BTBD2 message contains 255 nucleotides that are
89% GC-rich and are predicted to encode the N-terminus
of a 525 amino acid protein.
• BTBD1 and BTBD2 mRNA were detected in all human
tissues tested. BTBD1 mRNA was highly expressed in tes-
tes, heart and skeletal muscle. BTBD2 was more highly ex-
pressed in skeletal muscle. Only a single mRNA species
was present for each BTBD1 and BTBD2.
• Putative orthologs of BTBD1 and BTBD2 are found in C.
elegans (58% identities, 429 residues; 2% gaps, F38H4.7)
and  D. melanogaster (46% identities, 437 residues, 3%
gaps, CG5319).
• Two paralogs of BTBD1 and BTBD2 are present in the
human genome (CAC22147 and AF353674).
Materials and Methods
Plasmid construction
To construct the bait expression plasmid (pGBD-cTOP1),
the core domain of TOP1 (cTOP1, amino acids 198–651)
was amplified by PCR (sense primer: 5'-CGGAATTCGAA-
GAGGAACAGAAGTGGAAATGG-3'; antisense primer: 5'-
CGGGATCCTTAAATCTTAGTTTGCAAGTTCATCAT-3')
and inserted into the vector pGBD (Clontech) cut with
EcoRI and BamHI. To construct the cTOP1 expression vec-
tor (pDBleu-TOP1c), cTOP1 was excised from pGBD-
cTOP1 with EcoRI and BamHI and inserted into the same
sites in pDBleu (ProQuest, Life Technologies).
To construct the GST-fusion protein expression vectors,
the BTBD inserts from the prey vector pPC86 were ampli-
fied using primers complementary to the BTBD coding re-
gions with additional Sma I and EcoR I restriction sites for
insertion into these sites in pGEX-2TK (Pharmacia). These
primer sequences can be found below under the Two Hy-
brid Screens section. All constructs were confirmed by se-
quencing using pGEX sequencing primers (Pharmacia
Cat# 27-1410-01 and 27-1411-01).
To construct the expression plasmid encoding C-terminal-
myc-tagged, full length BTBD2 (m-BTBD2F), the entire
coding region of BTBD2 (1–1575 bp) was amplified with
primers (Upper primer: 5' ATGGCGGCGGGT-
GGGAGCGGCGGGCGTGCGTCGTG-3', Lower primer:
5'-GGTGTAGAAGATGACCTCGGGGATCTGGCCGTC-
CTCCAC-3') containing BamH I and Hind III cleavage
sites and inserted into pCMV-Tag 5 vector (Stratagene) cut
with BamH I and Hind III. To construct the expression
Figure 5
Effect of BTBD2 on TOP1 activity in vitro.A.Supercoil relaxa-
tion activity. HeLa cell nuclear extract containing TOP1 was
mixed with GST-BTBD2 or GST alone for 15 min on ice
before the addition of supercoiled DNA. The reactions were
then incubated for 0–24 min at 30°C before stopping with
SDS. The location of relaxed and supercoiled topoisomers
are indicated (R and SC). B.DNA nicking at a strong TOP1
cleavage site. GST or GST-BTBD2 was incubated with TOP1
for 20 min at room temperature before the addition of a 36
bp 3' end-labeled DNA [24]. Cleavage reactions were contin-
ued for another 20 min before stopping with SDS. Lane 1:
DNA alone; lane 2: + TOP1 (1.2 ng/reaction); lane 3: same +
10 µM camptothecin; lanes 4–8: reactions contained 0.25 µ g
GST and 10 µ M camptothecin; lanes 9–13 contained 0.25 µg
GST-BTBD2 + 10 µM camptothecin; lanes 4 & 9: no TOP1
added; lanes 5 & 10: 1.2 ng TOP1; lanes 6 & 11: 0.4 ng TOP1;
lanes 7 & 12: 0.3 ng TOP1; lanes 8 & 13: 0.1 ng TOP1). C. As
in B, but using a 161 bp substrate DNA [25]. Numbering of
cleavage sites according to Pommier et al. [25] is indicated
on the right side.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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plasmid encoding C-terminal-myc-tagged truncated
BTBD2 having the N-terminal half the BTB domain delet-
ed (m-BTBD2T), the coding region of BTBD2 from the
second ATG to almost the end of the 3'-UTR (445–2542
bp) was amplified with primers (Upper primer: 5'-ATGT-
TCAACGGGGGAATGGCCACAACATC-3', Lower primer:
5'-GGGGAGGACGCAGGTTCCAGGAGT-3') containing
BamH I and Hind III cleavage sites and inserted into
pCMV-Tag 3 vector (Stratagene) cut with BamH I and
Hind III.
Two hybrid screens
pGBD-cTOP1 was co-transfected with the HeLa cell li-
brary (Clontech, Cat. no. HL4000AA) into strain PJ69-4A
(MATa, trp 1-190 leu2-3, 112 ura3-52 his3-200 gal4 gal80
LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ)[41].
Strong expression of full length GALDB-TOP1 in PJ69-4A
was verified by Western blotting with antibodies to both
TOP1 and GALDB (not shown). Additionally, the Pro-
Quest two-hybrid system was used because the low copy
CEN plasmids may decrease the probability of obtaining
weakly interacting false positives that could result from
high concentrations of the two-hybrid proteins. In the
ProQuest screens, pDBleu-TOP1c was co-transfected with
a HeLa cell cDNA library (Life Technologies Cat. No.
11287-018) according the manufacturer protocols.
Clones that tested positive in the two-hybrid assays were
sequenced across the GAL4AD-prey junction into the cod-
ing regions of the prey inserts. Sequences were grouped
into cDNA contigs using the SeqMan II program of DNAS-
TAR (LASERGENE).
C-terminal deletions for mapping the interactions using
two-hybrid assays were constructed using the exonuclease
III/mung bean nuclease method (C-terminal deletions,
Exonuclease III/Mung Bean Nuclease Deletion kit,
Cat#460, NEW ENGLAND BioLabs company). N-termi-
nal deletions, in addition to the series obtained through
two-hybrid screening, were constructed by amplifying the
two-hybrid cDNA clones using primers containing Sma I
and EcoR I at the N- and C-terminus, respectively, and in-
serting them into both pPC86 and pGEX-2TK vectors. The
sense primer sequences are as follows: BTBD1: U1 (395-
482aa) 5'-GACCCCGGGGAATGATACCGGCTTTAGTT-
GTGA-3', U2 (342-482aa) 5'-GACCCCGGGCTGGGGTT-
ACAGTGGGACGAGT-3', U3 (213-482aa) 5'-
GACCCCGGGAAGTGCAGAAGGGTTTACT-3', U4 (303-
482aa) 5'-GACCCCGGGAAACCTCTTTCTTCATTTTACT-
GT-3', The same antisense primer was used for all ampli-
fications: 5'-
CGGAATTCTTTGTGGCCATTTATGTTTTTGAC-3'. The
sense primers for amplification of truncated BTBD2 frag-
ments were: U1 (504-525aa) 5'-GACCCCG-
GGCTACGCGGCCGGGAACAACAATG-3', U2 (460-
525aa) 5'-GACCCCGGGGGTGCTGCCCAACGTCAAC-
TACAC-3', U3 (404-525aa) 5'-GACCCCGGGCGTGGT-
GGGATTTGGGCTGTATGG-3', U4 (289-525aa) 5'-
GACCCCGGGCCGCTGGTCCGAGGCCGAGTGTC-3'.
The same antisense primer was used for all amplifications:
5'-CGGAATTCAACCCCGTCCTGATGCTGAGAAAG-3'
Northern blots
Multiple tissue Northern blots containing 2 µg poly (A) +
RNA (Human Multiple Tissue Northern Blot IV and Hu-
man Multiple Tissue Northern Blot; Catalog numbers:
7766-1 and 7760-1; CLONTECH) were hybridized with
32P-labeled human cDNA probes for TOP1(nucleotides
212–1661, GenBank accession number J03250), BTBD1
(nucleotides 84–3196, GenBank accession number
AF355402) or BTBD2 (nucleotides 1229–2668, GenBank
accession number AF355797) in Rapid-hyb buffers (Am-
ersham Life Science, RPN1635). Hybridization and wash-
ing was carried out according to the manufacturer
instructions.
Isolation of the BTBD2 coding region
The longest BTBD2 cDNA obtained from two-hybrid
screening (2413 bp) contained an ORF starting at the 5'
end. To obtain the full coding region, four independent
cDNA libraries were screened using a nested PCR strategy
with upper primers complementary to the vectors and two
nested lower primers complementary to BTBD2 (5'-
TCGTCCGAGTAGAGAAAC-3' and 5'-TCCACGTCG-
GGCAGCTCAATCTCC-3'). 5'-RACE (Life Technologies)
was also used to try to identify longer clones using several
different lower primers. Reverse transcription was also
performed at 70°C using the thermophilic Tth polymerase
Figure 6
Localization of BTBD2 and co-localization with TOP1. HeLa
cells were transfected with: A, GFP-tagged TOP1 lacking a
nuclear localization (GFP-pTI-6); B, full length BTBD2 con-
taining a C-terminal myc tag (m-BTBD2F); C, truncated
BTBD2 having the N-terminal half the BTB domain deleted
(m-BTBD2T); D, GFP-pTI-6 and m-BTBD2F; and E, GFP-
pTI-6 and m-BTBD2T.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/1
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with magnesium as the cofactor to enable it to use mRNA
as a template. None of these strategies was successful.
To determine whether the mRNA contained the BTBD2
gene sequences directly upstream of the longest cDNA
clone, RT-PCR was used with a sense primer complemen-
tary to the predicted start codon. The primers for reverse
transcription were complementary to exon 2 (LO and LI,
see below). PolyA+ RNA was reverse transcribed using Tth
polymerase (Promega) at 70°C for 20 min. The resulting
products were amplified using nested PCR with the Ad-
vantage-GC 2 PCR kit (CLONTECH, Cat# K-1913-Y) and
two 30 cycle rounds with each cycle having two steps (de-
naturation 94°C, 30 sec.; annealing and extension 68°C, 3
min; UO: 5'-ATGGCGGCGGGTGGGAGCGGCGGGCGT-
GCGTCGTG-3'; UI: 5'-CGGGCCCCGGGACAGACG-3';
LO: 5'-CGGGCAGCTCAATCTCCGTGGATG-3'; LI: 5'-TT-
GTGGCCATTCCCCCGTTGAACA-3'). To amplify the 306
bp fragment, two rounds of PCR were used: the first round
used the LO and UO primers, and the second round used
the LO and UI. To amplify the 460 bp fragment, two
rounds of PCR were also used, the LO and UO in the first
round, and the LI and the UO in the second round.
GST Pull Down Assay
E. coli containing plasmids encoding GST-BTBD1 or GST-
BTBD2 were grown to an O.D. of 0.3 at 25°C, and 2%
EtOH was added just prior to induction with 0.1 mM
IPTG for 8 hrs. E. coli extracts were prepared using a French
Pressure Cell Press (American Instrument Company, Sil-
ver Spring, MD). For the GST-pull-down assay 5 µg of GST
or the GST-fusion proteins were mixed with 150 µl HeLa
cell nuclear extracts (5 ×  106 cells/ml) and incubated for 2
hr at 4°C (0.25 M NaCl). The bead pellets were then




HeLa nuclear extract (5 ng) in reaction buffer (100 mM
Tris.HCl, pH 7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM ED-
TA, 15 µg/ml BSA) was incubated with 5 µg of purified
GST or GST-BTBD2 on ice for 15 min before the addition
of 0.25 µg plasmid and incubation at 30°C for 0–24 min.
Reactions were stopped by adding SDS (1% final) and
proteinase K (0.5 mg/reaction).
DNA cleavage assays
Purified TOP1 was pre-incubated with GST or GST-BTBD2
for 20 min before addition of the DNA substrate, which
was either an end-labeled 36 bp fragment containing a
single strong TOP1 cleavage site [24], or a 161 bp PvuII-
HindIII fragment of pBluescript (Stratagene) [25]). End
labeling of the DNA substrates was as previously de-
scribed [24,25]. Cleavage reactions were continued for 20
min before stopping with 0.5% SDS.
Abbreviations
aa, amino acid; BTB: Broad-Complex, Tramtrack and Bric-
a-brac; GST, glutathione-S-transferase; NLS, nuclear local-
ization signal; ORF, open reading frame; RT-PCR, reverse
transcription – polymerase chain reaction; TOP1, DNA
topoisomerase I.
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